Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer

Abstract

GnRH agonists increase the risk of clinical fracture in men with prostate cancer.

Mapping the prescriptiome to fractures in men—a national analysis of prescription history and fracture risk

“…Previous studies, including analysis of the present dataset [12], have shown an increased occurrence of fractures in patients with prostate cancer treated with androgen deprivation [45][46][47][48][49]. We also found a slightly increased risk of all (including hip) fractures in patients on insulin, also classified as tentative.…”

Medication-induced osteoporosis

“…Patients with at least nine treatments within the first year were 62% more likely to suffer a fragility fracture [35].…”

Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX™

“…One important cause of osteoporosis in adult men is androgen deprivation or withdrawal therapy (ADT) for prostate cancer. Men who are treated by orchiectomy or with analogs of gonadotropin-releasing hormone to suppress the pituitary and/or with androgen-receptor-blocking agents are at high risk for bone loss, osteoporosis, and fracture [2][3][4][5]. In a retrospective 4-year study of 288 men undergoing androgen deprivation therapy, Lopez et al [6] reported that the incidence of peripheral fractures was 1.9 per 100 patient-years in the men undergoing ADT compared to 0.5 in a large control group.…”